BioCentury
ARTICLE | Clinical News

Phase III results for Biogen's Amevive

June 12, 2001 7:00 AM UTC

BGEN said that its Amevive recombinant LFA-2 fusion protein met the primary end point of 75% or greater reduction of psoriasis area and severity index (PASI) score in two worldwide Phase III trials of...